拉米夫定联合复方牛胎肝提取物治疗肝纤维化的临床疗效及安全性评价

发布时间：2018-03-21 20:57

  本文选题：复方牛胎肝提取物片　切入点：乙型病毒性肝炎　出处：《中国临床药理学杂志》2015年12期 　论文类型：期刊论文

【摘要】：目的评价拉米夫定联合复方牛胎肝提取物片治疗慢性乙型病毒性肝炎(慢性乙肝)患者肝纤维化的临床疗效及安全性。方法将66例慢性乙肝患者随机分为对照组34例和试验组32例。对照组给予口服拉米夫定100 mg qd,疗程为6个月;试验组在对照组的基础上,给予口服复方牛胎肝提取物片80 mg,tid,疗程为6个月。比较2组患者治疗前后的Ⅲ型前胶原、玻璃酸等肝纤维化指标、肝穿刺活检炎症评分、肝纤维化评分以及不良反应发生率。结果治疗6个月后,2组患者肝纤维化指标较治疗前均有明显好转,但试验组血清玻璃酸、层黏连蛋白和Ⅲ型前胶原指标明显低于对照组(P0.05)。治疗后,试验组肝穿刺活检肝炎症评分及肝纤维化评分显著低于对照组(P0.05)。试验组不良反应发生率为29.41%,对照为21.88%,2组比较差异无统计学意义(P0.05)。结论拉米夫定联合复方牛胎肝提取物片可显著改善慢性乙肝患者肝纤维化程度,预防肝损伤。
[Abstract]:Objective to evaluate the efficacy and safety of lamivudine combined with compound bovine fetal liver extract tablets in the treatment of liver fibrosis in patients with chronic hepatitis B. methods 66 patients with chronic hepatitis B were randomly divided into control group. 34 cases and 32 cases in the test group. The control group was given 100mg / d lamivudine orally for 6 months. On the basis of the control group, the experimental group was given 80 mg of compound bovine fetal liver extract tablets for 6 months. The hepatic fibrosis indexes such as type 鈪，

本文编号：1645513